AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage company developing disruptive therapies that have the potential to transform patients’ lives in a single dose.

Stock Quote

Press Releases
October 22, 2019
AVROBIO Appoints Holly May as Chief Commercial Officer
Company developing commercial strategies and operational capabilities to support future product launches as investigational gene therapies advance through clinic Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct.